SCHEMBL803236

SCHEMBL803236

C=C(C)C(=O)Oc1ccc(-c2cc(F)c(OC(=O)C(=C)C)c(F)c2)c(F)c1F

nearest known ligand 0.33

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
FFAR4 Q5NUL3 3/20 0.32
PTGS2 P35354 2/20 0.32
FFAR1 O14842 2/20 0.31
PTGS1 P23219 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31
GRIN2B Q13224 2/20 0.31
TUBB1 Q9H4B7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18869267 0.93 FFAR4 (0.37) FFAR4PTGS2FFAR1PTGS1TUBB1
SCHEMBL17355034 0.92 PTGS2 (0.33) ELANECYP4F2CYP4A11FFAR4PTGS2
SCHEMBL18411559 0.92 ELANE (0.35) ELANE
SCHEMBL17791487 0.92 EGFR (0.32)
SCHEMBL20343005 0.91
SCHEMBL18435898 0.90
SCHEMBL22310947 0.90
SCHEMBL19498686 0.90 ELANE (0.36) ELANE
SCHEMBL18468236 0.89
SCHEMBL19186360 0.89 PTGER2 (0.35) FFAR4FFAR1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 US disclosed
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 US disclosed
EP-4400561-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-07-17 EP disclosed
WO-2024132893-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
WO-2024133363-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
WO-2024126567-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-06-20 WO disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
EP-3924447-B1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2024-01-24 EP disclosed
EP-4306615-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-01-17 EP disclosed
WO-2010133278-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2010-11-25 WO disclosed
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2010-10-28 US disclosed
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2010-10-28 US disclosed
EP-2243812-A2 Liquid crystal display Merck Patent GmbH (DE) 2010-10-27 EP disclosed
US-7807068-B2 reacting 4-halo-2,6-difluorophenol with protecting group, dehalogenating to form protected phenol ether group, reacting with boronic acid/ester, coupling in presence of catalyst, deblocking, etherifying, esterifying; for optical, electro-optical and electronic use, liquid-crystal media and displays MERCK PATENT GESELLSCHAFT (DE) 2010-10-05 US disclosed
US-7807068-B2 reacting 4-halo-2,6-difluorophenol with protecting group, dehalogenating to form protected phenol ether group, reacting with boronic acid/ester, coupling in presence of catalyst, deblocking, etherifying, esterifying; for optical, electro-optical and electronic use, liquid-crystal media and displays MERCK PATENT GESELLSCHAFT (DE) 2010-10-05 US disclosed
WO-2010089092-A1 LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2010-08-12 WO disclosed
US-20090141215-A1 POLYMERIZABLE COMPOUNDS MERCK PATENT GESELLSCHAFT (DE) 2009-06-04 US disclosed
US-20090141215-A1 POLYMERIZABLE COMPOUNDS MERCK PATENT GESELLSCHAFT (DE) 2009-06-04 US disclosed
EP-2065361-A2 Polymerisable compounds Merck Patent GmbH (DE) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY KLK3, BPHL, LPXN ELANE 402/4885CYP4F2 2874/4885CYP4A11 3215/4885
US-20090141215-A1 POLYMERIZABLE COMPOUNDS VCL, LCP1, LPXN ELANE 957/4885CYP4F2 4218/4885CYP4A11 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.